Last reviewed · How we verify
HBOC-201
At a glance
| Generic name | HBOC-201 |
|---|---|
| Also known as | Hemopure, hemoglobin glutamer - 250 (bovine) |
| Sponsor | Jonathan H. Waters |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Expanded Access Protocol Using HBOC-201
- Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia (NA)
- Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia
- HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option
- Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization (PHASE2)
- Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia (PHASE2)
- Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization (PHASE2)
- A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |